Aurora Cannabis Debuts High-Potency ‘Black Jelly’ Strain in Poland, Expanding European Medical Access
Aurora Cannabis has launched a new medical cannabis cultivar. It is called ‘Black Jelly’. This new strain is now available in Poland. The company announced this significant event on December 11, 2025. This launch marks an expansion of Aurora’s offerings. It also highlights their growing presence in Europe.
A New Sativa Strain Arrives
Black Jelly is a proprietary cultivar. It boasts high potency. This strain has 27% THC. It contains less than 1% CBD. Its genetics come from Alien Cake 3030 × T037. The terpene profile offers notes of black licorice. It also includes fruity undertones. Aurora cultivated Black Jelly in Canadian facilities. These facilities meet GACP and EU-GMP standards. This ensures pharmaceutical-grade quality.
Aurora’s Growing Presence in Poland
Poland is a key market for Aurora. The company has a long history there. Aurora first gained approval to supply medical cannabis to Poland in 2018. They were the first non-government business to do so. This early entry provided a significant advantage. The Polish market has seen growth. It is now one of Europe’s fastest-growing medical cannabis markets. Aurora’s existing portfolio in Poland includes Farm Gas and Sourdough. Black Jelly joins these established brands. The company aims to provide reliable options. High-potency medical cannabis is in demand. Aurora focuses on meeting prescriber and patient needs.
European Market Strategy
Aurora Europe is a key part of the company’s strategy. The company has a strong European footprint. Aurora Deutschland GmbH is a subsidiary. They have expanded operations across the continent. This includes Germany, Italy, and Nordic countries. Poland represents another vital step. Aurora’s facilities are EU GMP certified. This certification is crucial for European exports. The company sees Europe as a growing market. Medical cannabis is being legalized in many countries. Poland’s market alone is significant. It was valued at nearly 200 million euros in 2023. Import limits have also increased. This suggests potential for further growth.
Impact on Patients and Prescribers
The introduction of Black Jelly offers new choices. Patients seeking high-THC options benefit. Prescribers now have more tools. These tools help tailor treatments. The strain is sativa-dominant. It may offer stimulating effects. Its profile suggests potential uses for various conditions. The Polish market is evolving. Increased supply and variety are positive news. Aurora emphasizes quality and consistency. This is vital for pharmaceutical-grade products. The company has over a decade of experience. This experience aids their market leadership.
Future Outlook
Aurora continues to invest in innovation. Their genetic breeding program is advanced. They use premium cultivation techniques. Hang-drying and curing are key processes. The company is focused on profitable growth. High-margin medical cannabis sales are a priority. Poland is a target for future expansion. Aurora seeks to capitalize on market trends. This launch is part of a broader strategy. It reinforces Aurora’s global medical cannabis presence. The medical cannabis news in Poland continues to trend upwards. This represents significant events for patient access.
Aurora Cannabis is strengthening its position. The launch of Black Jelly is a testament to this. It shows their commitment to European patients. This move supports the growing medical cannabis ecosystem.
